Söndag 27 April | 10:39:52 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-27 09:50 Kvartalsrapport 2025-Q3
2025-08-28 09:50 Kvartalsrapport 2025-Q2
2025-06-25 N/A X-dag ordinarie utdelning PRLD 0.00 SEK
2025-06-24 N/A Årsstämma
2025-05-30 09:50 Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-27 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning PRLD 0.00 SEK
2024-02-21 - Bokslutskommuniké 2023
2023-11-27 - Extra Bolagsstämma 2023
2023-11-27 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning PRLD 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-30 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-08-04 - Extra Bolagsstämma 2022
2022-05-23 - X-dag ordinarie utdelning PRLD 0.00 SEK
2022-05-20 - Årsstämma
2022-05-20 - Kvartalsrapport 2022-Q1
2022-02-22 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-31 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning PRLD 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-21 - X-dag ordinarie utdelning PRLD 0.00 SEK
2020-05-20 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-20 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning PRLD 0.00 SEK
2018-11-20 - Kvartalsrapport 2018-Q3
2018-08-28 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning PRLD 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-14 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-22 - X-dag ordinarie utdelning PRLD 0.00 SEK
2017-05-19 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Prolight Diagnostics utvecklar testsystem inom POCT (Point of care testning). Testerna används utanför sjukhuslaboratorium för att möjliggöra snabba bedömningar av patienters hälsa. Bolagets POCT-Plattform är i utveckling med avsikt att mäta flera biomarkörer samtidigt. En viktig del i arbetet är således att korta ner tiden för provresultaten, särskilt viktigt för patienter med hjärtbesvär. Bolaget grundades år 1999 och har sitt huvudkontor i Lund.
2023-02-16 08:00:00

Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has successfully completed the SBRI Healthcare phase 2 award, accelerating development of its unique digital immunoassay.

Psyros received the SBRI Healthcare phase 2 grant of approximately 1 million GBP last year, requiring the completion of certain milestones. Psyros has now met or exceeded all the milestones and work packages set out in the agreement, including developing a research level fully functional prototype of the single molecule counting instrument. The six prototype units will serve to accelerate the development of the reagent cartridge and to define the requirements for the development of a commercially viable platform.

“The SBRI Healthcare awards help the NHS to develop new technologies and solutions to address some of the biggest healthcare challenges facing society. We have selected these innovations because they have the potential to make a big difference to patients. By supporting the most promising innovations the NHS will continue to evolve, helping meet more patients’ needs and encouraging more innovators to come forward with ideas that make a difference,” said Matt Whitty, CEO of the Accelerated Access Collaborative (AAC), an initiator of SBRI Healthcare.

“The SBRI grant has not only allowed us to accelerate the development of the concept of the digital immunoassay but has also been a way for us to measure ourselves against other technologies and we are very happy for this acknowledgement. This puts us in a good position to bring a high-sensitive troponin assay to the market,” said Ulf Bladin, CEO of Prolight Diagnostics.

About SBRI Healthcare
SBRI Healthcare is an Accelerated Access Collaborative (AAC) initiative, supported by the Academic Health Science Networks (AHSNs) and managed by LGC Group. SBRI Healthcare aims to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice. Since 2008, the NHS has backed the SBRI programme, supporting over 200 companies to develop innovative technologies that match the needs of the health service. Many of these are now selling into global markets and delivering innovation to the healthcare community. Previous SBRI Healthcare competitions have called for technological and innovative solutions to, for example, change people’s behaviour in order to reduce the impact of obesity and alcohol related diseases, how to live well with dementia and improved medicine management. www.sbrihealthcare.co.uk